Serum soluble CD23 level correlates with subsequent development of AIDS- related non-Hodgkin's lymphoma

Jennifer R. Schroeder, Alfred J. Saah, Donald R. Hoover, Joseph Bernard Margolick, Richard F Ambinder, Otoniel Martinez-Maza, Elizabeth Crabb Breen, Lisa Paula Jacobson, Daina Variakojis, David T. Rowe, Haroutune K. Armenian

Research output: Contribution to journalArticle

Abstract

The cytokine soluble CD23 (sCD23) has been shown to act as a B cell growth factor and to be elevated in serum prior to development of AIDS- related non-Hodgkin's lymphoma (AIDS NHL). To further characterize the elevation of serum sCD23 in AIDS NHL patients and investigate its potential as a diagnostic test, a matched case-control study of AIDS NHL (n = 101) was nested within the Multicenter AIDS Cohort Study. Serum sCD23 was measured in cases' and controls' serum specimens at three different time periods (0-6, 6- 12, and 12-18 months) and CD4+ thresholds (0-99, 100-199, and 200-299 cells//μl) prior to the case's NHL diagnosis. Changes in serum sCD23 over time were examined in AIDS NHL cases relative to controls, and t tests were performed to determine whether cases' serum sCD23 exceeded that of controls at each time period and CD4+ threshold. Overall, cases' median serum sCD23 levels were approximately double those of controls. Serum sCD23 concentration was positively correlated with lymphocyte counts for both cases and controls. The difference in cases' and controls' serum sCD23 levels became greater as AIDS NHL diagnosis date approached: in the 18 months preceding the case's NHL diagnosis, serum sCD23 was stable in cases but dropped in controls. Although this difference was statistically significant (P <0.05), it was not clinically significant. It is unlikely that serum sCD23 would make a useful test for AIDS NHL because the magnitude of the difference between cases and controls was small and there was no change in serum sCD23 in cases that would indicate disease.

Original languageEnglish (US)
Pages (from-to)979-984
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume8
Issue number11
StatePublished - Nov 1999
Externally publishedYes

Fingerprint

AIDS-Related Lymphoma
Non-Hodgkin's Lymphoma
Serum
Lymphocyte Count
Routine Diagnostic Tests

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Serum soluble CD23 level correlates with subsequent development of AIDS- related non-Hodgkin's lymphoma. / Schroeder, Jennifer R.; Saah, Alfred J.; Hoover, Donald R.; Margolick, Joseph Bernard; Ambinder, Richard F; Martinez-Maza, Otoniel; Breen, Elizabeth Crabb; Jacobson, Lisa Paula; Variakojis, Daina; Rowe, David T.; Armenian, Haroutune K.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 8, No. 11, 11.1999, p. 979-984.

Research output: Contribution to journalArticle

Schroeder, JR, Saah, AJ, Hoover, DR, Margolick, JB, Ambinder, RF, Martinez-Maza, O, Breen, EC, Jacobson, LP, Variakojis, D, Rowe, DT & Armenian, HK 1999, 'Serum soluble CD23 level correlates with subsequent development of AIDS- related non-Hodgkin's lymphoma', Cancer Epidemiology Biomarkers and Prevention, vol. 8, no. 11, pp. 979-984.
Schroeder, Jennifer R. ; Saah, Alfred J. ; Hoover, Donald R. ; Margolick, Joseph Bernard ; Ambinder, Richard F ; Martinez-Maza, Otoniel ; Breen, Elizabeth Crabb ; Jacobson, Lisa Paula ; Variakojis, Daina ; Rowe, David T. ; Armenian, Haroutune K. / Serum soluble CD23 level correlates with subsequent development of AIDS- related non-Hodgkin's lymphoma. In: Cancer Epidemiology Biomarkers and Prevention. 1999 ; Vol. 8, No. 11. pp. 979-984.
@article{fc6427651fb14e3185f57b17c9e59273,
title = "Serum soluble CD23 level correlates with subsequent development of AIDS- related non-Hodgkin's lymphoma",
abstract = "The cytokine soluble CD23 (sCD23) has been shown to act as a B cell growth factor and to be elevated in serum prior to development of AIDS- related non-Hodgkin's lymphoma (AIDS NHL). To further characterize the elevation of serum sCD23 in AIDS NHL patients and investigate its potential as a diagnostic test, a matched case-control study of AIDS NHL (n = 101) was nested within the Multicenter AIDS Cohort Study. Serum sCD23 was measured in cases' and controls' serum specimens at three different time periods (0-6, 6- 12, and 12-18 months) and CD4+ thresholds (0-99, 100-199, and 200-299 cells//μl) prior to the case's NHL diagnosis. Changes in serum sCD23 over time were examined in AIDS NHL cases relative to controls, and t tests were performed to determine whether cases' serum sCD23 exceeded that of controls at each time period and CD4+ threshold. Overall, cases' median serum sCD23 levels were approximately double those of controls. Serum sCD23 concentration was positively correlated with lymphocyte counts for both cases and controls. The difference in cases' and controls' serum sCD23 levels became greater as AIDS NHL diagnosis date approached: in the 18 months preceding the case's NHL diagnosis, serum sCD23 was stable in cases but dropped in controls. Although this difference was statistically significant (P <0.05), it was not clinically significant. It is unlikely that serum sCD23 would make a useful test for AIDS NHL because the magnitude of the difference between cases and controls was small and there was no change in serum sCD23 in cases that would indicate disease.",
author = "Schroeder, {Jennifer R.} and Saah, {Alfred J.} and Hoover, {Donald R.} and Margolick, {Joseph Bernard} and Ambinder, {Richard F} and Otoniel Martinez-Maza and Breen, {Elizabeth Crabb} and Jacobson, {Lisa Paula} and Daina Variakojis and Rowe, {David T.} and Armenian, {Haroutune K.}",
year = "1999",
month = "11",
language = "English (US)",
volume = "8",
pages = "979--984",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Serum soluble CD23 level correlates with subsequent development of AIDS- related non-Hodgkin's lymphoma

AU - Schroeder, Jennifer R.

AU - Saah, Alfred J.

AU - Hoover, Donald R.

AU - Margolick, Joseph Bernard

AU - Ambinder, Richard F

AU - Martinez-Maza, Otoniel

AU - Breen, Elizabeth Crabb

AU - Jacobson, Lisa Paula

AU - Variakojis, Daina

AU - Rowe, David T.

AU - Armenian, Haroutune K.

PY - 1999/11

Y1 - 1999/11

N2 - The cytokine soluble CD23 (sCD23) has been shown to act as a B cell growth factor and to be elevated in serum prior to development of AIDS- related non-Hodgkin's lymphoma (AIDS NHL). To further characterize the elevation of serum sCD23 in AIDS NHL patients and investigate its potential as a diagnostic test, a matched case-control study of AIDS NHL (n = 101) was nested within the Multicenter AIDS Cohort Study. Serum sCD23 was measured in cases' and controls' serum specimens at three different time periods (0-6, 6- 12, and 12-18 months) and CD4+ thresholds (0-99, 100-199, and 200-299 cells//μl) prior to the case's NHL diagnosis. Changes in serum sCD23 over time were examined in AIDS NHL cases relative to controls, and t tests were performed to determine whether cases' serum sCD23 exceeded that of controls at each time period and CD4+ threshold. Overall, cases' median serum sCD23 levels were approximately double those of controls. Serum sCD23 concentration was positively correlated with lymphocyte counts for both cases and controls. The difference in cases' and controls' serum sCD23 levels became greater as AIDS NHL diagnosis date approached: in the 18 months preceding the case's NHL diagnosis, serum sCD23 was stable in cases but dropped in controls. Although this difference was statistically significant (P <0.05), it was not clinically significant. It is unlikely that serum sCD23 would make a useful test for AIDS NHL because the magnitude of the difference between cases and controls was small and there was no change in serum sCD23 in cases that would indicate disease.

AB - The cytokine soluble CD23 (sCD23) has been shown to act as a B cell growth factor and to be elevated in serum prior to development of AIDS- related non-Hodgkin's lymphoma (AIDS NHL). To further characterize the elevation of serum sCD23 in AIDS NHL patients and investigate its potential as a diagnostic test, a matched case-control study of AIDS NHL (n = 101) was nested within the Multicenter AIDS Cohort Study. Serum sCD23 was measured in cases' and controls' serum specimens at three different time periods (0-6, 6- 12, and 12-18 months) and CD4+ thresholds (0-99, 100-199, and 200-299 cells//μl) prior to the case's NHL diagnosis. Changes in serum sCD23 over time were examined in AIDS NHL cases relative to controls, and t tests were performed to determine whether cases' serum sCD23 exceeded that of controls at each time period and CD4+ threshold. Overall, cases' median serum sCD23 levels were approximately double those of controls. Serum sCD23 concentration was positively correlated with lymphocyte counts for both cases and controls. The difference in cases' and controls' serum sCD23 levels became greater as AIDS NHL diagnosis date approached: in the 18 months preceding the case's NHL diagnosis, serum sCD23 was stable in cases but dropped in controls. Although this difference was statistically significant (P <0.05), it was not clinically significant. It is unlikely that serum sCD23 would make a useful test for AIDS NHL because the magnitude of the difference between cases and controls was small and there was no change in serum sCD23 in cases that would indicate disease.

UR - http://www.scopus.com/inward/record.url?scp=0032696986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032696986&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 979

EP - 984

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -